On January 5, 2023, Metagenomi, a genetic medicines company with a versatile portfolio of next-generation gene editing tools, announced the close of a Series B extension financing, co-led by Novo Holdings A/S, Catalio Capital Management and SymBiosis, with participation from new and existing investors. This $100 million financing brings the total Series B proceeds to $275 million, with over 30 investment groups participating. Wilson Sonsini Goodrich & Rosati advised Metagenomi on patent matters related to the transaction.

With a healthy cash runway off the heels of successful partnerships with Moderna and Ionis Pharmaceuticals, this additional capital will enable Metagenomi to advance its lead therapeutic programs through preclinical development and into clinical proof-of-concept. Furthermore, the company plans to nominate additional therapeutic targets to its proprietary genetic medicines pipeline, fueled by its automated discovery engine and versatile gene editing toolbox, to expand into additional preclinical proof-of-concept studies.

The Wilson Sonsini team that advised Metagenomi on patent matters related to the transaction included Ali Alemozafar, Michael Hostetler, Derrick Rowe, and Brandon Tavshanjian.

For more information, please see Metagenomi’s press release.